Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures

Annals of Surgical Oncology

Volumn 4, Issue 5, 1997, Pages 432-439

  Euhus, David M ^a,b   Kimura, Lucille ^a   Arnold, Bruce ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Cytotoxicity; Human breast cancer; Interleukin 2

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CD4 CD8 RATIO; CELL CULTURE; COCULTURE; CYTOTOXICITY; FEMALE; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; PAGET NIPPLE DISEASE;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD56; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CD4-CD8 RATIO; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-2; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0031178815     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02305558     Document Type: Article

References (28)

1. Runnebaum IB, Kreienberg R. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. Hybridoma 1995;14:153-7.
2. Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995;136:4298-303.
3. Miller A, McBride W, Dubinett S, et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunological properties with IL-2. Blood 1993;82:3686-94.
4. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
5. Tsai S, Gansbacher B, Tait L, et al. Induction of anti-tumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993;85:546-53.
6. Fearon E, Pardoll D, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of anti-tumor responses. Cell 1990;60:397-403.
7. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
8. Matory Y, Chen M, Goedegebuure P, Eberlein T. Anti-tumor activity of three mouse mammary cancer cell lines following cytokine gene transfection. 47th Annual Cancer Symposium of the Society of Surgical Oncology, March 17-20, 1994, Houston, TX.
9. Eamonn C, Clary B, DiMaio J, et al. Inhibition of breast cancer metastasis by cytokine gene-modified tumor vaccination in tumor-bearing mice. JAMA 1994;272:1485.
10. Karp SE, Farber A, Salo JC, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 1993; 150:896-908.
11. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994;1:436-50.
12. Musiani P, Modesti A, Brunetti M, et al. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes. Nat Immun 1994;13:93-101.
13. Rosen P. The pathobiology of breast carcinoma. In: Harris J, Hellman S, Henderson I, eds. Breast Diseases. Philadelphia: JB Lippincott, 1987;147-209.
14. Baxevanis CN, Dediussis GVC, Papadoupoulos NG, et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994;74:1275-82.
15. McGregory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious adenovirus type 5. Virology 1988;163:614-7.
16. Graham FL, Prevac L. Gene transfer and expression protocols. In: Murray FJ, ed. Methods in Molecular Biology, Vol. 7. Clifton, NJ: Humana Press, 1991.
17. Wright SC, Wilbur SM. Biochemical characterization of natural killer cytotoxic factors. Adv Exp Med 1985;184:179-81.
18. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci USA 1989;86:1249-53.
19. Miescher S, Whiteside TL, Carrel S, et al. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986;136:1899.
20. Uchiyama A, Hoon DSB, Morisaki T, et al. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 1993;53:949-52.
21. Sairenji M, Yanoma S, Motohashi H, et al. Induction of cytolytic activity of lymphocytes from carcinomatous pleural effusion by IL-2 and autologous tumor cells. Biotherapy 1994;6:283-90.
22. Euhus D. High efficiency adenoviral-mediated gene transfer into human breast cells. 48th Annual Cancer Symposium of the Society of Surgical Oncology, March 23-26, 1995, Boston, MA.
23. Yannelli JR, Hyatt C, Johnson S, et al. Characterization of human tumor cell lines transduced with the cDNA encoding either necrosis factor alpha (TNF-α) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77-90.
24. Ortaldo JR, Mason A, Overton R. Lymphokine activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986;164: 1193-205.
25. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T-lymphocytes to cytolysis. J Exp Med 1986;164:814-25.
26. Euhus D, Kimura L. Characterization of lymphocytes infiltrating breast cancers and surrounding normal breast tissue. Breast Cancer Res Treat 1995;37(suppl):109.
27. Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21:1673-9.
28. Yasumura S, Higuchi K, Hioki O, et al. Induction of allogeneic tumor- and lymphokine-activated lymphocytes against hepatocellular carcinoma. J Gastroenterol Hepatol 1992;7:136-41.